SCHEMBL15748877

SCHEMBL15748877

CS[C@H]1O[C@@H](c2ccc(C)c(Cc3ccc(OCCCC(=O)NC(C)(C)C(=O)N4CCN(C)CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 19/20 1.00
SLC5A2 P31639 10/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20787349 0.93 SLC5A1 (0.87) SLC5A1SLC5A2
SCHEMBL20787317 0.93 SLC5A1 (0.86) SLC5A1SLC5A2
SCHEMBL15748717 0.92 SLC5A1 (1.00) SLC5A1SLC5A2
SCHEMBL20787370 0.91 SLC5A1 (0.85) SLC5A1SLC5A2
SCHEMBL20787346 0.91 SLC5A1 (0.96) SLC5A1SLC5A2
SCHEMBL16162883 0.89 SLC5A1 (0.85) SLC5A1SLC5A2
SCHEMBL20787103 0.88 SLC5A1 (0.82) SLC5A1SLC5A2
SCHEMBL20787097 0.88 SLC5A1 (1.00) SLC5A1SLC5A2
SCHEMBL16169587 0.87 SLC5A1 (0.85) SLC5A1SLC5A2
SCHEMBL24029614 0.87 SLC5A1 (0.90) SLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489226-B1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS INC (US) 2021-02-17 EP disclosed
EP-3489226-B1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS INC (US) 2021-02-17 EP disclosed
EP-3489226-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 Lexicon Pharmaceuticals, Inc. (US) 2019-05-29 EP disclosed
EP-3489226-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 Lexicon Pharmaceuticals, Inc. (US) 2019-05-29 EP disclosed
EP-2925735-B1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS INC (US) 2019-03-13 EP disclosed
EP-2925735-B1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS INC (US) 2019-03-13 EP disclosed
US-10106569-B2 Inhibitors of sodium glucose transporter 1 for constipation LEXICON PHARMACEUTICAL, INC. (US) 2018-10-23 US disclosed
US-20180244708-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-08-30 US disclosed
US-9688710-B2 Inhibitors of sodium glucose cotransporter 1 LEXICON PHARMACEUTICALS, INC. (US) 2017-06-27 US disclosed
US-9688710-B2 Inhibitors of sodium glucose cotransporter 1 LEXICON PHARMACEUTICALS, INC. (US) 2017-06-27 US disclosed
US-20160326205-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-11-10 US disclosed
US-20160326205-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-11-10 US disclosed
US-20160326205-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-11-10 US disclosed
US-9200025-B2 Inhibitors of sodium glucose cotransporter 1 LEXICON PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-9200025-B2 Inhibitors of sodium glucose cotransporter 1 LEXICON PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-9200025-B2 Inhibitors of sodium glucose cotransporter 1 LEXICON PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-20140309178-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS, INC. (US) 2014-10-16 US disclosed
US-20140309178-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS, INC. (US) 2014-10-16 US disclosed
US-20140309178-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS, INC. (US) 2014-10-16 US disclosed
WO-2014081660-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 LEXICON PHARMACEUTICALS, INC. (US) 2014-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106569-B2 Inhibitors of sodium glucose transporter 1 for constipation SLC5A1, SLC5A2, SLC10A2 SLC5A1 1/4885SLC5A2 2/4885
US-20180244708-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 SLC5A1, SLC5A2, SLC2A1 SLC5A1 1/4885SLC5A2 2/4885
US-20140309178-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 SLC5A1, SLC5A2, SLC2A1 SLC5A1 1/4885SLC5A2 2/4885
US-20160326205-A1 INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 SLC5A1, SLC5A2, SLC2A1 SLC5A1 1/4885SLC5A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.